tetano
Editor, Senior Moderator
Cell Rep
. 2025 Jun 19;44(7):115859.
doi: 10.1016/j.celrep.2025.115859. Online ahead of print. The SARS-CoV-2 trigger highlights host interleukin 1 genetics in Epstein-Barr virus reactivation
Petra Schneiderova[SUP] 1 [/SUP], Jan Mizera[SUP] 2 [/SUP], Arootin Gharibian[SUP] 3 [/SUP], Gayane Manukyan[SUP] 4 [/SUP], Milan Raska[SUP] 1 [/SUP], Petr Gajdos[SUP] 5 [/SUP], Petr Kosztyu[SUP] 1 [/SUP], Samuel Genzor[SUP] 2 [/SUP], Milos Kudelka[SUP] 5 [/SUP], Milan Sova[SUP] 6 [/SUP], Jakub Savara[SUP] 3 [/SUP], Alena Borikova[SUP] 7 [/SUP], Bishu Shrestha[SUP] 1 [/SUP], Zuzana Mikulkova[SUP] 1 [/SUP], Ladislav Stepanek[SUP] 7 [/SUP], Jiri Kufa[SUP] 2 [/SUP], Petr Jakubec[SUP] 2 [/SUP], Eva Kriegova[SUP] 8 [/SUP]
Affiliations
Studies in large cohorts exposed to the same triggers associated with Epstein-Barr virus (EBV) reactivation and the follow-up of post-acute outcomes may uncover the pathomechanisms of autoimmune conditions and EBV-related cancer. We investigated a large cohort of individuals infected with SARS-CoV-2 infection reporting long COVID (LC) symptoms for positive serological markers of recent EBV reactivation (viral capsid antigen [VCA] immunoglobulin [Ig]M, VCA IgA, and early antigen D IgG), host interleukin (IL)1 and IL10 genetics, and immune response. Recent EBV reactivation occurs more frequently in individuals with a genetic risk of EBV reactivation in the IL1RN, IL1A, and IL1B genes associated with an elevated ratio of IL-1 receptor antagonist (IL-1Ra)/IL-1β and a higher latent EBV load in blood. High levels of anti-VCA IgA serve as a strong marker of recent EBV reactivation, which is associated with objective long-term pulmonary dysfunction in LC. Our data highlight the association between host IL1 genetics and EBV reactivation.
Keywords: Anti-viral capsid antigen IgA; CP: Immunology; CP: Microbiology; EBV serology; IL1 polymorphisms; anti-EBV antibody; coronavirus disease 2019; herpes virus reactivation; latent EBV DNA load; long COVID symptoms; post-acute sequelae; recent EBV reactivation.
. 2025 Jun 19;44(7):115859.
doi: 10.1016/j.celrep.2025.115859. Online ahead of print. The SARS-CoV-2 trigger highlights host interleukin 1 genetics in Epstein-Barr virus reactivation
Petra Schneiderova[SUP] 1 [/SUP], Jan Mizera[SUP] 2 [/SUP], Arootin Gharibian[SUP] 3 [/SUP], Gayane Manukyan[SUP] 4 [/SUP], Milan Raska[SUP] 1 [/SUP], Petr Gajdos[SUP] 5 [/SUP], Petr Kosztyu[SUP] 1 [/SUP], Samuel Genzor[SUP] 2 [/SUP], Milos Kudelka[SUP] 5 [/SUP], Milan Sova[SUP] 6 [/SUP], Jakub Savara[SUP] 3 [/SUP], Alena Borikova[SUP] 7 [/SUP], Bishu Shrestha[SUP] 1 [/SUP], Zuzana Mikulkova[SUP] 1 [/SUP], Ladislav Stepanek[SUP] 7 [/SUP], Jiri Kufa[SUP] 2 [/SUP], Petr Jakubec[SUP] 2 [/SUP], Eva Kriegova[SUP] 8 [/SUP]
Affiliations
- PMID: 40540397
- DOI: 10.1016/j.celrep.2025.115859
Studies in large cohorts exposed to the same triggers associated with Epstein-Barr virus (EBV) reactivation and the follow-up of post-acute outcomes may uncover the pathomechanisms of autoimmune conditions and EBV-related cancer. We investigated a large cohort of individuals infected with SARS-CoV-2 infection reporting long COVID (LC) symptoms for positive serological markers of recent EBV reactivation (viral capsid antigen [VCA] immunoglobulin [Ig]M, VCA IgA, and early antigen D IgG), host interleukin (IL)1 and IL10 genetics, and immune response. Recent EBV reactivation occurs more frequently in individuals with a genetic risk of EBV reactivation in the IL1RN, IL1A, and IL1B genes associated with an elevated ratio of IL-1 receptor antagonist (IL-1Ra)/IL-1β and a higher latent EBV load in blood. High levels of anti-VCA IgA serve as a strong marker of recent EBV reactivation, which is associated with objective long-term pulmonary dysfunction in LC. Our data highlight the association between host IL1 genetics and EBV reactivation.
Keywords: Anti-viral capsid antigen IgA; CP: Immunology; CP: Microbiology; EBV serology; IL1 polymorphisms; anti-EBV antibody; coronavirus disease 2019; herpes virus reactivation; latent EBV DNA load; long COVID symptoms; post-acute sequelae; recent EBV reactivation.